

FILE 'MEDLINE' ENTERED AT 13:03:33 ON 19 DEC 2008

E PARKIN N T/AU

L1 63 S E3-E5
L2 30 S L1 AND (PROTEASE)
L3 12 S L2 AND AMPRENAVIR
L4 2 S L3 AND (HYPERSUSCEPTIB? OR MORE SUSCEPTIBLE OR INCREASED SUSC
L5 195770 S (HIV OR HUMAN IMMUNODEFICIENCY VIRUS)
L6 12397 S L5 AND PROTEASE
L7 566 S L6 AND AMPRENAVIR
L8 13 S L7 AND (HYPERSUSCEPTIB? OR MORE SUSCEPTIBLE OR INCREASED SUSC
L9 11 S L8 NOT L4

FILE 'WPIDS' ENTERED AT 13:10:59 ON 19 DEC 2008

E PARKIN N T/IN

L10 31 S E3 OR E4
L11 17 S L10 AND PROTEASE
L12 9 S L11 AND AMPRENAVIR
L13 2 S L12 AND (HYPERSUSCEPTIBLE OR MORE SUSCEPTIBLE OR INCREASED SU

WEST Search History

[Hide Items](#) | [Restore](#)

DATE: Friday, December 19, 2008

| Hide? | Set | Name | Query | Hit Count |
|-------------------------------------|---------------------|--|-----------------------|---------------------------|
| <i>DB=USPT; PLUR=YES; OP=AND</i> | | | | |
| <input checked="" type="checkbox"/> | L20 | L19 and (hypersusceptibilitiy or (more adj susceptible) or (increased adj susceptibility)) | | 61 |
| <input checked="" type="checkbox"/> | L19 | L18 and amprenavir | | 500 |
| <input checked="" type="checkbox"/> | L18 | L17 and (protease adj inhibitor\$) | | 6454 |
| <input checked="" type="checkbox"/> | L17 | L16 and protease | | 13730 |
| <input checked="" type="checkbox"/> | L16 | (human immunodeficiency virus or HIV) | | 34522 |
| <input checked="" type="checkbox"/> | L15 | L14 and amprenavir | | 8 |
| <input checked="" type="checkbox"/> | L14 | (parkin.in. and neil.in. and t.in.) | | 14 |
| <i>DB=PGPB; PLUR=YES; OP=AND</i> | | | | |
| <input checked="" type="checkbox"/> | L12 | L11 not L1 | | 31 |
| <input checked="" type="checkbox"/> | L11 | L10 and (HIV.ti. or (human.ti. adj immunodeficiency.ti. adj virus.ti)) | | 31 |
| <input checked="" type="checkbox"/> | L10 | L8 and (hypersusceptibility or (more adj susceptible) or (increased adj susceptibility)) | | 368 |
| <input checked="" type="checkbox"/> | L8 | L7 and amprenavir | | 1559 |
| <input checked="" type="checkbox"/> | L7 | L6 and (protease adj inhibitor\$) | | 10641 |
| <input checked="" type="checkbox"/> | L6 | L5 and protease | | 21616 |
| <input checked="" type="checkbox"/> | L5 | (human immunodeficiency virus or HIV) | | 43315 |
| <input checked="" type="checkbox"/> | L4 | L3 and protease.ti. | | 8 |

| | | | |
|---|----|--|----|
| □ | L3 | L2 and (hypersusceptibility or more susceptible or increased susceptibility) | 21 |
| □ | L2 | L1 and (protease or amprenavir) | 21 |
| □ | L1 | (neil.in. and parkin.in.) | 25 |


END OF SEARCH HISTORY

HIV DRUG RESISTANCE DATABASE
A RESOURCE FOR THE UNDERSTANDING AND MANAGEMENT OF DRUG RESISTANCE IN HIV INFECTION

Project: PROTEASE | QUINUPPURIN | RIBAVIRIN | RIBAVIPEP | RIBAVIPEP-CHEMICAL | RIBAVIPEP-PROT

Detailed Protease Phenotype Query

| | | | |
|----------------------|------|------------|----|
| Mutations | P39S | References | 13 |
| Drugs | APV | Isolates | 23 |
| Assay | ANY | Results | 23 |
| WithNoOtherMajorMuts | No | | |



Drug susceptibility results of sequences matching input query are shown in the table below. Literature references are indicated, as well as the isolate name and type and a list of major, minor and other mutations. The fold resistance to the indicated antiretroviral drug is indicated in the last column of the table. Data is also summarized above in graphical format. Blue bars indicate the range of resistance of those sequences with no *major drug resistance mutations and red bars indicate the fold resistance of sequences matching the input query. The total number of sequences(n), the median fold resistance(m), as well as the first(Q1) and third quartile(Q3) are indicated.

Page 1 from Result 1 to Result 23 from Total 23 Phenotype results


| Author (ref) | Type | Isolates | P39S Major Muts | P39S Minor Muts | Other | Method | Drug | Fold |
|-----------------|----------|------------|----------------------|-----------------|---|-----------|------|------|
| Candia (2000) | Clinical | ptEW32 | I24I, E24V, Y22A, | I19R, A71V | R5V, M38I, P39S, S22V, L83P | Condra-98 | APV | 2.0 |
| Dugana (2001) | Clinical | AD-pH4 | V32I, M46I,, V82A | I19R, A71V | R5V, N37S, P39S, R41K, L83P, V20P | Virologic | APV | 3.0 |
| Gonzales (2001) | Clinical | CA11056 | I96M | A71V, G73S | R5V, Q18H, K79, P36L, M38I, P39S, S22V, L83P, P2L | Virologic | APV | 1.4 |
| Dumanian (2002) | Clinical | AD-15 | | I19R | T12P, R5V, L19I, M38I, N37E, P39S, L83S | Viro | APV | 0.6 |
| Meagir (2002) | Clinical | SW31808 | V32I, I87V | I19R, A71T | T12A, I33V, G16E, P39S, R67K, I64V, P2V, F38L | Viro | APV | 2.6 |
| | | SW31814 | I54M | I19R | I19V, N37Q, P39S, R41K, L83P, V82I, F38L | Viro | APV | 4.3 |
| | | SW32168 | M46I,M, I80V | I19R, A71T | T12A, I33V, G16E, P39S, R67K, L83P, E4V, P72V, F38L | Viro | APV | 6.3 |
| Margol (2002) | Clinical | 4237368031 | | | K14R, L33V, N37I, P39S, R41V, D60E, E22V, I64V | Viro | APV | 0.6 |
| Grossman (2004) | Clinical | 17746Pr115 | | | G16E, V20P, M38I, P39S, R41V, D60E, E22V, L83P | Virologic | APV | 0.6 |



Home Overview Detailed Query References Methods About Contact Help

Detailed Protease Phenotype Query

| | | | |
|----------------------|------|------------|----|
| Nucleotides | 6500 | References | 11 |
| Drugs | APV | Isolates | 27 |
| Assay | ANY | Results | 28 |
| WithNoOtherMajorMuts | No | | |



Drug susceptibility results of sequences matching input query are shown in the table below. Literature references are indicated, as well as the isolate name and type and a list of major, minor and other mutations. The fold resistance to the indicated antiviral drug is indicated in the last column of the table. Data is also summarized above in graphical format. Blue bars indicate the range of resistance of those sequences with no 'major drug resistance mutations' and red bars indicate the fold resistance of sequences matching the input query. The total number of sequences(n), the median fold resistance(m), as well as the first(Q1) and third quartile(Q3) are indicated.

Page 1 from Result 1 to Result 28 from Total 28 Phenotype results


| Author (#) | Type | Isolates | #MajorMuts | #MinorMuts | Other | Method | Drug | Fold |
|--------------------|----------|------------|------------------------------------|------------|--|-----------|------|------|
| Verma (2000) | Clinical | LVMBF260 | | L10I, M45V | R3V, Q16E, K20R, E35D, M38I, P93T, R41K, R52Y, L63T, P66D, H69K, L89M | Viroc | APV | 1.5 |
| | | LVMP411 | M45I | | L5F, K14R, R5V, K20R, E35D, M38I, N37D, R41K, R52K, L63T, B66D, L89M | Viroc | APV | 0.4 |
| Gonzales (2001) | Clinical | CA35548 | V23I, F53L, S49V, V82D, L89M | L10I, A71V | L3BM, E34Q, N37H, Q61E, L63E, R44V, B66D | Virologic | APV | 3.2 |
| Kamuf (2001) | Clinical | DK-284 | | | R3V, N37N, R52V, L83HPC, E64LM, S66DE, V77I, L89ML | Virologic | APV | 0.5 |
| | | DK-284 | | | R3V, M38I, R41K, L63P, B66D, V70P | Virologic | APV | 0.8 |
| Gumina (2002) | Clinical | AD-16 | | | R3V, E35D, R41K, R57V, Q61N, R44V, B66D | Viroc | APV | 0.5 |
| | | AD-68 | | | L33P, B66D, R52R | Viroc | APV | 0.6 |
| Magat (2002) | Clinical | 287736691 | I54L, V82F | L10I, Q68E | R41K, L63T, B66D, R72V, V77I | Viroc | APV | 10.1 |
| | | 4009367801 | | | M38I, N37E, R57K, L63P, R44V, B66D, K70R | Viroc | APV | 0.5 |

HIV DRUG RESISTANCE DATABASE

Version 7.0 (2018-07-19) - Last updated 2018-07-19 14:19:46 UTC

Detailed Protease Phenotype Query

| | | | |
|----------------------|------|------------|-----|
| Mutations | HEQK | References | 17 |
| Drugs | APV | Isolates | 181 |
| Assay | ANY | Results | 182 |
| WithNoOtherMajorMuts | No | | |



Drug susceptibility results of sequences matching input query are shown in the table below. Literature references are indicated, as well as the isolate name and type and a list of major, minor and other mutations. The fold resistance to the indicated antiretroviral drug is indicated in the last column of the table. Data is also summarized above in graphical format. Blue bars indicate the range of resistance of those sequences with no *major drug resistance mutations* and red bars indicate the fold resistance of sequences matching the input query. The total number of sequences(n), the median fold resistance(m), as well as the first(Q1) and third quantile(Q3) are indicated.

Pages 1 [2]

Back To
Query

Page 1 from Result 1 to Result 100 from Total 182 Phenotype results


| Author ref | Type | Isolates | Phenotype | Number of Muts | Other | Method | Drug Fold |
|---------------|----------|-----------|-----------|----------------|---|-----------|-----------|
| Yerins (2000) | Clinical | LV31HALD | | 1101 | I13V, G16A, M35I, R41K, D68E, Q81E, C87G, H89Y, L89M | Viroc | APV 0.4 |
| | | LV45HALD | | | I13V, K14R, G17E, K20I, M35I, N37S, R41K, I64M, H69K, L89M | Viroc | APV 0.3 |
| | | LVMSFE260 | | 1101, M46V | I13V, G16E, K20R, E36D, M35I, P39T, R41K, I62V, H33T, E56D, H89Y, L89M | Viroc | APV 1.6 |
| | | LVMP1387 | | | I13V, G16A, M35I, N37D, D68E, Q81E, I83T, Q87E, H89Y, V77I, L89M | Viroc | APV 0.4 |
| | | LVMP560 | | | I13V, G16A, N37D, D68E, Q81E, I83T, Q87E, H89Y, V77I | Viroc | APV 0.2 |
| | | LVMP540 | | 1101 | I13V, E36D, M35I, R41K, R67K, H89K, L89M | Viroc | APV 0.2 |
| Kamel (2001) | Clinical | DN-1584 | | 1101 | I13V, H5V, E36D, M35I | Virologic | APV 0.8 |

HIV DRUG RESISTANCE DATABASE

SEARCH PHENOTYPE SEARCHES BY ISOLATE SEARCH BY DRUG SEARCH BY ASSAY SEARCH BY REFERENCE

Detailed Protease Phenotype Query

| | | | |
|---------------------|------|------------|-----|
| Mutations | L89M | References | 22 |
| Drugs | APV | Isolates | 163 |
| Assay | ANY | Results | 163 |
| WithNoOtherMajorMut | No | | |



Drug susceptibility results of sequences matching input query are shown in the table below. Literature references are indicated, as well as the isolate name and type and a list of major, minor and other mutations. The fold resistance to the indicated antiretroviral drug is indicated in the last column of the table. Data is also summarized above in graphical format. Blue bars indicate the range of resistance of those sequences with no 'major drug resistance mutations' and red bars indicate the fold resistance of sequences matching the input query. The total number of sequences(n), the median fold resistance(m), as well as the first(Q1) and third quartile(Q3) are indicated.

Pages 1 [2]

Back To
Query

Page 1 from Result 1 to Result 163 from Total 163 Phenotype results

| Author (n) | Type | Isolates | MajorDRMs | MinorDRMs | Other | Method | Drug | Fold |
|------------------|----------|----------|------------------------|------------------|---|--------------|------|------|
| Condra (2006) | Clinical | pJW24 | I64Y, V82F | L10I, L39I | Q18E, K20R, E36D, M36I, N37S, L63P, L89M, S3L | Condra-06 | APV | 1.0 |
| | | pJW36 | I64Y, V82F, L89M | L10I, L39I | Q18E, K20R, E36D, M36I, N37S, L63P, L89M, S3L | Condra-06 | APV | 4.0 |
| | | pJW48 | M46I, V82F, I84V | L10I, L39I | T12S, R3Y, M36I, R4V, L89M | Condra-06 | APV | >8.0 |
| Yoshimura (2009) | Clinical | Yoshi-2 | L24I, M46L, I64Y, V82A | L10I | I5V, K20R, M36I, I62V, L63P, K70G, L89M | Generic-PBMC | APV | 16.0 |
| Calzetta (2009) | Clinical | V020053 | V32I, M46L, V32A, L50M | L10I, Q58E, A71V | I62V, L63P, L89M | Viroc | APV | 7.0 |
| | | V020427 | V32I, M46L, I64V | L10I, Q58E, A71V | L39M, E36D, R57K, L63P, K70R, F72K, L89M | Viroc | APV | 29.0 |
| | | V208998 | L24I, M46I, I64V, V82A | L10I | I39V, I62V, L63P, I64V, L89M | Viroc | APV | 8.0 |
| | | V213886 | L33F, I60V | L10F, T74S | I3V, M46X, L39A, V77I, L89M | Viroc | APV | 14.0 |
| | | V216984 | L33F, E4M, L89M | Q58E, G73C | T12Z, L18X, D60E, L63P, V77I, L89M, S3L | Viroc | APV | 31.0 |